Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks0Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by cancer family

Pancreas16Breast32Prostate29Lung and pleura38Colorectal23Esophagus and stomach20Liver, bile duct and gallbladder29Kidney and bladder42Brain and nervous system38Blood, lymph and bone marrow38Skin and eye28Head and neck13Thyroid and endocrine8Gynecologic28Sarcoma and soft tissue22Germ cell and testis3Thymus3Multiple or not classified from the title48
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Reader
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Prostate Adenocarcinoma (TCGA, PanCancer Atlas)

cBioPortal DataHub · study prad_tcga_pan_can_atlas_2018 · www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018

Study metadataOpen database (ODbL)PubMed 12TCGA PanCancer AtlasApproximately 1 min read

Table of Contents

1. Summary2. Study description3. Citation & PubMed4. Source & licence

Summary

Prostate Adenocarcinoma (TCGA, PanCancer Atlas) is a study catalogued by cBioPortal DataHub under the cancer-type code prad. EvidenceHelix groups it with prostate studies and lists it in the TCGA PanCancer Atlas collection.

This page is catalog metadata only: what the study is called and where to find it. It does not report findings, mutation frequencies or patient numbers, and it is not clinical guidance.

What this page is

Study description

Prostate Adenocarcinoma TCGA PanCancer data. The original data is here (https://gdc.cancer.gov/about-data/publications/pancanatlas). The publications are here (https://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html).

Text as published in the source's study metadata.

Citation & PubMed

TCGA, Cell 2018

Linked PubMed records: PMID 29625048, PMID 29596782, PMID 29622463, PMID 29617662, PMID 29625055, PMID 29625050, PMID 29617662, PMID 30643250, PMID 32214244, PMID 29625049, PMID 29850653, PMID 36334560

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier
prad_tcga_pan_can_atlas_2018
Short name
Prostate (TCGA PanCan 2018)
Source cancer-type code
prad
Reference genome
not given
Source access groups
PUBLIC;PANCAN
Original study
View on cBioPortal
Metadata file
meta_study.txt at e1b75cd25b
Database licence
ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data. TCGA data are available under the Broad Institute GDAC TCGA Analysis Pipeline License; TCGA-derived records are preliminary or legacy releases.

Citations

TCGA, Cell 2018

  • PubMed record 29625048 ↗
  • PubMed record 29596782 ↗
  • PubMed record 29622463 ↗
  • PubMed record 29617662 ↗
  • PubMed record 29625055 ↗
  • PubMed record 29625050 ↗
  • PubMed record 29617662 ↗
  • PubMed record 30643250 ↗
  • PubMed record 32214244 ↗
  • PubMed record 29625049 ↗
  • PubMed record 29850653 ↗
  • PubMed record 36334560 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

  • Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)

    MSK-IMPACT sequencing of 424 matched tumor-normal samples from patients with metastatic castration-sensitive prostate cancer. Germline alterations are not shown here.

    ProstateMSK studiesSource code pradPubMed 1
  • Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)

    Exome sequencing of 61 prostate cancer tumor/normal pairs (50 metastatic CRPCs and 11 high-grade localized prostate cancers). Generated by Arul Chinnaiyan's and Scott Tomlins' labs at the University of Michigan.

    ProstateOther published and consortium studiesSource code pradPubMed 1
  • Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)

    Whole exome sequencing of 444 castrate resistant prostate cancer tumor/normal pairs. SU2C-PCF Dream Team: Precision Therapy for Advanced Prostate Cancer.

    ProstateOther published and consortium studiesSource code pradPubMed 1
  • Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)

    Whole-exome sequencing of 150 metastatic prostate cancer tumor/normal pairs by the SU2C/PCF Dream Team.

    ProstateOther published and consortium studiesSource code pradPubMed 1
  • Neuroendocrine Prostate Cancer (Multi-Institute, Nat Med 2016)

    Whole exome sequencing of 114 metastatic tumor/normal pairs to understand genomic overlap between castration resistant adenocarcinoma (CRPC-Adeno) and neuroendocrine histologies (CRPC-NE).

    ProstateOther published and consortium studiesSource code pradPubMed 1
  • Prostate Adenocarcinoma (Broad/Cornell, Cell 2013)

    Whole genome sequencing of 57 prostate tumor and matches normal tissues.

    ProstateOther published and consortium studiesSource code pradPubMed 1
  • Prostate Adenocarcinoma (Broad/Cornell, Nat Genet 2012)

    Whole-exome sequencing of 112 prostate adenocarcinomas and matched normal samples. Generated by Levi Garraway's lab at the Broad Institute and Mark Rubin's lab at Cornell.

    ProstateOther published and consortium studiesSource code pradPubMed 1
  • Prostate Adenocarcinoma (CPC-GENE, Nature 2017)

    Whole-genome/exome sequencing of 477 prostate samples from CPC-GENE and public data sets, including TCGA-PRAD.

    ProstateOther published and consortium studiesSource code pradPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

At a glance

Study ID
prad_tcga_pan_can_atlas_2018
Cancer family
Prostate
Collection
TCGA PanCancer Atlas
Source code
prad
PubMed links
12

Family and collection are EvidenceHelix groupings derived from the title; the source code is the source's own.

Related studies See all →

  • Metastatic castration-sensitive prostate cancer (MSK, Clin Cancer Res 2020)MSK studies
  • Metastatic Prostate Adenocarcinoma (MCTP, Nature 2012)Other published and consortium studies
  • Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS 2019)Other published and consortium studies
  • Metastatic Prostate Cancer (SU2C/PCF Dream Team, Cell 2015)Other published and consortium studies

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Original sources

  • Study on cBioPortal ↗
  • Source metadata file ↗
  • PubMed 29625048 ↗
  • PubMed 29596782 ↗
  • PubMed 29622463 ↗

Study metadata from cBioPortal DataHub (e1b75cd25b, synced 2026-10-31), available under the ODC Open Database License (ODbL) 1.0; attribution required. EvidenceLib is a research-education resource, not medical advice. Sources & licence